Inhibin as a marker for granulosa‐cell tumors

Lappöhn, Richard E.; Burger, H. G.; Bouma, J; Bangah, Mohan; Krans, M.; Bruijn, Hwa de

doi:10.1016/0020-7292(90)90940-m

Cited by 47 publications

(77 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The focus in ovarian cancer has been on the role of the inhibin subunit (Lappohn et al 1989). There is also an important role for inhibin and, in particular, its subunit in prostate cancer.…”

Section: Inhibin Activin and Prostate Cancer Inhibins And Prostate Cmentioning

confidence: 99%

The role of inhibins and activins in prostate cancer pathogenesis.

Dowling¹,

Risbridger²

2000

Endocrine-Related Cancer

View full text Add to dashboard Cite

Successful prostate cancer diagnosis and management continue to provide challenges for the clinician. While interventions aimed at the containment of both early and late disease continue to fail in a significant number of patients, the search for answers must incorporate an analysis of the processes of normal and aberrant growth and development within the gland itself. Inhibin and its structurally related protein, activin, are members of the transforming-growth-factor β (TGFβ) superfamily. Originally identified as regulators of FSH, these proteins are now recognised to have widespread biological functions. This might be expected of proteins that are structurally homologous to TGFβ itself, which is recognised to have regulatory roles in both normal and malignant prostate tissue. The aim of this review is to examine the relationship between inhibins, activins and their related proteins and the development of prostate cancer. The homology with TGF, the pluripotent effects of activin on various tissues and the roles for inhibins in ovarian cancer make activins and inhibins candidate growth factors for involvement at multiple sites in the progression from benign disease to cancer. In compiling this review, we aim to delineate the changes in inhibins and activins in this pathway and in doing so implicate their potential roles in the progression of carcinogenesis. We will compare the changes in inhibin and its related proteins in prostate cancer to those that are known in ovarian cancer. We will discuss the similarities and differences between the putative role of activins and TGFβ in prostate carcinogenesis. The importance of this review lies in demonstrating that inhibin, an endocrine hormone, and its related proteins may contribute to endocrine-related cancers, such as that of the prostate gland.

show abstract

Section: Inhibin Activin and Prostate Cancer Inhibins And Prostate Cmentioning

confidence: 99%

The role of inhibins and activins in prostate cancer pathogenesis.

Dowling¹,

Risbridger²

2000

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…A value of 10.5 pg/ml was taken as cut of value for premenopausal patients. 4,5 In postmenopausal patients, any detectable assay of Inhibin was taken as positive. In case of CA125, 35 IU/ml was taken as positive.…”

Section: Methodsmentioning

confidence: 99%

“…Women with granulosa-cell tumors of the ovary have elevated serum Inhibin concentrations and measurements of this hormone are useful marker for persistent or recurrent granulosa-cell tumors. 3 CA125 is effective in detecting serous ovarian cancers, whereas Inhibin is effective in detecting the mucinous and granulosa cell cancer. The present study is an effort to assess the suitability of combined test using Inhibin and CA 125 to diagnose patients with ovarian cancer.…”

mentioning

confidence: 99%

Combined use of CA 125 and Inhibin as tumor marker for detection of ovarian cancer in comparison to CA 125 or Inhibin alone

Dubbewar¹,

Pathak²,

Biswas³

et al. 2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Ovarian cancers are diagnosed at an advanced stage. Early diagnosis is the key to reduce death from ovarian cancer. The present study is an effort to assess the suitability of combined test using CA 125 and Inhibin for early diagnosis of ovarian cancer as compared to CA125 or Inhibin alone.Methods: Fifty women with clinical suspicion of ovarian malignancy attending Gynae OPD were enrolled. All of these women were subjected to estimation of CA 125 and Inhibin levels prior to surgical intervention. A value of 35 IU/ml was taken as positive for CA 125. For Inhibin, 10.5 pg/ml was taken as cut off for premenopausal patients, whereas, any detectable assays were taken as positive for postmenopausal patients. The results were analyzed after establishing final histopathology of the disease.Results: Out of 50 patients recruited, 30 (60%) were found to have carcinoma ovary and 20 (40%) were found to have benign diseases. Out of 30 cases of carcinoma ovary, CA125 was raised in 81% of cases and Inhibin was raised in 78% of cases. For detection of carcinoma ovary, CA 125 was found to have a sensitivity of 90% and specificity of 60% with a positive predictive value of 77% and negative predictive value of 80% which were statistically significant. Sensitivity and specificity of serum Inhibin for the same was 86.6% and 20% respectively. The positive and negative predictive value were 61.9% and 50%, which were not statistically significant. Sensitivity and specificity of combined CA125 and Inhibin were 100% and 30% respectively. The positive and negative predictive value were 68.1% and 100% respectively, which were statistically significant.Conclusions: Combined use of CA125 and Inhibin has got better sensitivity and specificity in detection of ovarian cancer in comparison to CA 125 or Inhibin used alone.

show abstract

“…(Wiater and Vale, 2003;Farnworth et al, 2007). This antagonistic effect of inhibin is amplified in the presence of the inhibin receptor, TGFb receptor III (TGFbRIII), also known as betaglycan.The first study that linked inhibin to reproductive cancers showed that serum inhibin increased in women with granulosa cell tumours of the ovary (Lappohn et al, 1989) and inhibin currently serves as a robust biomarker for this cancer. A direct biological function for inhibin in carcinogenesis was demonstrated by Matzuk et al (1992) when they created the inhibin-a subunit (INHa) knockout mouse.…”

mentioning

confidence: 99%

Elevated level of inhibin-α subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer

et al. 2009

View full text Add to dashboard Cite

The biological function of inhibin-a subunit (INHa) in prostate cancer (PCa) is currently unclear. A recent study associated elevated levels of INHa in PCa patients with a higher risk of recurrence. This prompted us to use clinical specimens and functional studies to investigate the pro-tumourigenic and pro-metastatic function of INHa. We conducted a cross-sectional study to determine a link between INHa expression and a number of clinicopathological parameters including Gleason score, surgical margin, extracapsular spread, lymph node status and vascular endothelial growth factor receptor-3 expression, which are well-established prognostic factors of PCa. In addition, using two human PCa cell lines (LNCaP and PC3) representing androgen-dependent and -independent PCa respectively, we investigated the biological function of elevated levels of INHa in advanced cancer. (Wiater and Vale, 2003;Farnworth et al, 2007). This antagonistic effect of inhibin is amplified in the presence of the inhibin receptor, TGFb receptor III (TGFbRIII), also known as betaglycan.The first study that linked inhibin to reproductive cancers showed that serum inhibin increased in women with granulosa cell tumours of the ovary (Lappohn et al, 1989) and inhibin currently serves as a robust biomarker for this cancer. A direct biological function for inhibin in carcinogenesis was demonstrated by Matzuk et al (1992) when they created the inhibin-a subunit (INHa) knockout mouse. Both sexes developed gonadal sex-cord stromal tumours with high penetrance and developed tumours in their adrenal glands after castration, showing that INHa can act as a tumour suppressor. Subsequent mouse model studies revealed a complex network of interactions involving inhibin, activin and other modifiers in the development and progression of gonadal and adrenal tumours in INHa-deficient mice (reviewed in Risbridger et al, 2001). Although it is clear that total inhibin as a serum test has utility in the initial detection and prognosis of certain types of ovarian cancers, the biological function of inhibin in tumourigenesis is far from clear.We have observed both up-and down-regulation of INHa expression in prostate cancer (PCa) tissues dependent on the stage

show abstract

Inhibin as a marker for granulosa‐cell tumors

Cited by 47 publications

References 0 publications

The role of inhibins and activins in prostate cancer pathogenesis.

The role of inhibins and activins in prostate cancer pathogenesis.

Combined use of CA 125 and Inhibin as tumor marker for detection of ovarian cancer in comparison to CA 125 or Inhibin alone

Elevated level of inhibin-α subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer

Contact Info

Product

Resources

About